HOME >> BIOLOGY >> NEWS
Early environmental exposure may accelerate age-related neurodegeneration

WASHINGTON, DC June 27, 2007 -- Exposure to iron during the first weeks of life in combination with exposure later in life to a common herbicide may contribute to the subsequent degeneration of brain cells associated with the onset of Parkinsons disease (PD), according to a new study in mice. The findings also showed that a compound that protects cells in the body from damage from certain forms of oxygen, a kind of antioxidant, could suppress such neural degeneration.

Previous studies indicated that both early exposure to iron and later exposure to the herbicide paraquat independently increase oxidative stressan environment in which damage from levels of reactive oxygen is more likelyin dopamine-producing regions of the brain, areas that are affected by PD. Julie Andersen, PhD, and her team at the Buck Institute for Age Research found that feeding iron to newborn mice made them more susceptible to paraquat, which increases levels of harmful forms of oxygen and damages dopamine-producing neurons as they grew older. The study appears in the June 27 issue of The Journal of Neuroscience.

The importance of the study is that it points to a possible role of common mechanisms triggered by iron and paraquat as important in PD, and suggests that therapies that block their effects would be worth testing in patients, says Marie-Francoise Chesselet, MD, PhD, of UCLA, who did not participate in the study.

Ten-day-old mice were fed iron for a week. At ages from two months to two years, they were then exposed to paraquat for three weeks. By examining their brains, Andersen and her team found that by the time the mice were a year old, early iron consumption exacerbated damage to brain cells caused by paraquat exposure. The effect was even more pronounced at two years of age, the human equivalent of 6070 years.

A subset of mice that received the antioxidant at the same time that they were exposed to paraquat exhibited reduced leve
'"/>

Contact: Sara Harris
sharris@sfn.org
202-962-4000
Society for Neuroscience
27-Jun-2007


Page: 1 2

Related biology news :

1. Early fire risk for mountains near Los Angeles
2. Early exposure to indoor fungus molecules may protect infants against future allergies
3. Early-stage sperm cells created from human bone marrow
4. Early Europeans unable to stomach milk
5. Early HIV treatment fails to restore memory T cells
6. Early Earth haze may have spurred life, says University of Colorado study
7. Early detection
8. Early family experience can reverse the effects of genes, UCLA psychologists report
9. Early to bed, early to rise
10. Early exposure to synthetic estrogen puts DES Daughters at higher risk for breast cancer
11. Top researcher-educators receive Presidential Early Career Award for Scientists and Engineers

Post Your Comments:
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: